(E)-5,5-diphenyl-2,4-pentadienoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-5,5-diphenyl-2,4-pentadienoic acid
• 英文别名: (E)-5,5-diphenylpenta-2,4-dienoic acid；5,5-diphenylpenta-2,4-dienoic acid；5,5-diphenyl-penta-2t,4-dienoic acid；5,5-Diphenyl-penta-2t,4-diensaeure；5,5-diphenyl-penta-2E,4-dienoic acid；(2E)-5,5-diphenylpenta-2,4-dienoic acid
• 化学式: C₁₇H₁₄O₂
• 分子量: 250.297
• InChiKey: VTMOVDSOOWNIBW-NTUHNPAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-5,5-diphenyl-2,4-pentadienoic acid 在 palladium-carbon 作用下， 以 甲醇 为溶剂， 以97.3%的产率得到5,5-diphenylpentanoic acid
  参考文献：
  名称：

  BENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

  摘要：

  公开号：

  EP1346987B1
• 作为产物：
  描述：

  (E)-methyl 5,5-diphenylpenta-2,4-dienoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以92%的产率得到(E)-5,5-diphenyl-2,4-pentadienoic acid
  参考文献：
  名称：

  通过芳基到乙烯基1,4-钯迁移/ Heck序列的高立体选择性合成1,3-二烯

  摘要：

  开发了一种有效的芳基到乙烯基1,4-钯迁移/ Heck序列，用于1,3-二烯的立体选择性合成。不仅对于在末端位置带有两个相似芳基的1,3-二烯，还观察到了较高的立体选择性，而且对那些构型显示不利于先前方法的化合物也观察到了高立体选择性。

  DOI：

  10.1002/anie.201801963

文献信息

• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• PENTADIENAMIDE DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2050734A1

  公开（公告）日：2009-04-22

  The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R3 represents a hydrogen atom or is combined together with R4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R5, R6, and R7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由式(I)表示的戊二烯酰胺衍生物:(其中R1代表取代或未取代的芳基或取代或未取代的芳香族杂环基；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物；R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基；R4代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物，或与R3及其相邻的氮原子结合形成取代或未取代的杂环基；R5、R6和R7可以相同也可以不同，每个代表氢原子或甲基)或其药学上可接受的盐等。
• Pentadieneamide compounds which have useful activity of treating a
  申请人：Hoffmann-La Roche Inc.

  公开号：US04975438A1

  公开（公告）日：1990-12-04

  Compounds of the formula ##STR1## Y is O or S, *A is paraphenylene or *--(CH.sub.2).sub.n --(X).sub.m --(CH.sub.2).sub.r --, X is O, S or --CH.dbd.CH--, n or r, independently, are integers from 0 to 3, s is an integer from 0 to 1, m is an integer from 0 to 1, provided that when m is 1, n+s must be at least 2, R.sub.1 and R.sub.2, independently, are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, Het, Aryl, R.sub.3, R.sub.4 and R.sub.8, independently, are hydrogen, lower alkyl, aryl, R.sub.5 and R.sub.6, independently, are hydrogen or lower alkyl, R.sub.7 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen, oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R.sub.6 and R.sub.7 are different, their enantiomers and racemic mixtures thereof, when R.sub.1 and R.sub.2 are different, their geometric isomers, and pharmaceutically acceptable acid addition salts thereof, are described. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.

  式为##STR1##的化合物，其中Y是O或S，*A是对苯基或*--(CH.sub.2).sub.n --(X).sub.m --(CH.sub.2).sub.r --，X是O，S或--CH.dbd.CH--，n或r分别是独立的0至3的整数，s是0至1的整数，m是0至1的整数，但当m为1时，n+s必须至少为2，R.sub.1和R.sub.2分别是氢，低烷基，环烷基，低烯基，Het，Aryl，R.sub.3、R.sub.4和R.sub.8分别是氢，低烷基，芳基，R.sub.5和R.sub.6分别是氢或低烷基，R.sub.7是氢，低烷基，环烷基，Het-低烷基或芳基，Het是一种单环5-或6-成员杂芳基或含有一或两个异原子（氮、氧和硫）的双环杂芳基基团，该基团可以被低烷基，卤素或芳基取代，星号表示连接点，当R.sub.6和R.sub.7不同时，它们的对映异构体和混合物，当R.sub.1和R.sub.2不同时，它们的几何异构体以及药学上可接受的酸盐也被描述。公式I的化合物表现为血小板活化因子（PAF）拮抗剂的活性，因此，它们对于具有过量血小板活化因子的疾病状态或预防和治疗心血管疾病，肺部疾病，免疫性疾病，炎症性疾病，皮肤病，休克或移植排斥反应是有用的。
• ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS
  申请人：——

  公开号：US20020028833A1

  公开（公告）日：2002-03-07

  Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1 V=O, S, NH or a bond; Ar can be unsubstituted or substituted benzimidazole, phenyl, biphenyl, pyridyl, naphthyl, quinoline, isoquinoline or indole; n=2-6; m=1-3; X=O (oxygen), S (sulfur), ═CH 2 , ═NH or H 2 ; R 1 and R 2 can independently be hydrogen, lower alkyl of from 1-4 carbon atoms, —(CH 2 ) n OR 6 , —(CH 2 ) n NR 3 R 4 , —(CH 2 ) n ′CONR 3 R 4 , —(CH 2 ) n ′COOR 6 , —(CH 2 ) r Ar′, where n′=0-6 r=0-4 R 3 and R 4 can independently be hydrogen, lower alkyl of from 1-4 carbon atoms, —(CH 2 ) n OR 6 , or —(CH 2 ) m —Ar′, which can be unsubstituted or substituted with up to 3 substitutents, where “Ar′” is phenyl, pyridyl, or indole; R 3 and R 4 may also be taken together to form a cyclic ring of 3-8 atoms which may also contain oxygen or the group NR 5 where R 5 can be hydrogen, lower alkyl of from 1-4 carbon atoms, cycloalkyl of from 5-12 carbon atoms, or —(CH 2 ) m -Phenyl, which can be unsubstituted or substituted with up to 3 substitutents; R 6 can be hydrogen, lower alkyl or (CH 2 ) m -Phenyl; m=1-3; R 1 and R 2 may be also taken together to form a ring of 3-8 atoms which may also contain oxygen or the group NR 5 , which ring may be substituted on one or more carbon atoms with the group NR 3 R 4 ; the subtituents are defined as: halogen, nitro, CF 3 , alkyl of from 1-12 carbon atoms; —(CH 2 ) r OR 6 —(CH 2 ) r NR 3 R 4 —(CH 2 ) r CONR 3 R 4 —(CH 2 ) r C(O)OR 6 or —(CH 2 ) r SO 2 —OR 6 ; R 7 , R 8 , R 9 and R 10 can each independently be hydrogen, lower alkyl or aryl; and R 7 and R 8 or R 9 and R 10 or X or R 2 when taken together can form a 5-7 membered ring including cycloalkyl, cycloalkenyl, aryl, or heteroaryl containing nitrogen, oxygen or sulfur.

  公式I的芳基烯酰胺衍生物或其药学上可接受的盐是新型MCP-1拮抗剂，因此在治疗炎症、动脉粥样硬化、再狭窄和免疫紊乱，如关节炎和移植排斥方面有用。其中，V=O，S，NH或键；Ar可以是未取代或取代苯并咪唑、苯基、联苯基、吡啶基、萘基、喹啉、异喹啉或吲哚；n=2-6；m=1-3；X=O（氧）、S（硫）、═CH2、═NH或H2；R1和R2可以独立地是氢、1-4碳原子的低烷基、—（CH2）nOR6、—（CH2）nNR3R4、—（CH2）n′CONR3R4、—（CH2）n′COOR6、—（CH2）rAr′，其中n=0-6，r=0-4；R3和R4可以独立地是氢、1-4碳原子的低烷基、—（CH2）nOR6或—（CH2）m—Ar′，其中“Ar′”可以是未取代或取代的苯基、吡啶基或吲哚，最多可以带有3个取代基；R3和R4也可以结合成为3-8个原子的环，该环也可以包含氧或基团NR5，其中R5可以是氢、1-4碳原子的低烷基、5-12碳原子的环烷基或—（CH2）m-苯基，最多可以带有3个取代基；R6可以是氢、低烷基或（CH2）m-苯基；m=1-3；R1和R2也可以结合成为3-8个原子的环，该环也可以包含氧或基团NR5，在其中一个或多个碳原子上取代基团NR3R4；取代基团的定义为：卤素、硝基、CF3、1-12碳原子的烷基；—（CH2）rOR6、—（CH2）rNR3R4、—（CH2）rCONR3R4、—（CH2）rC（O）OR6或—（CH2）rSO2—OR6；R7、R8、R9和R10可以各自独立地是氢、低烷基或芳基；当R7和R8或R9和R10或X或R2结合在一起时，可以形成一个包含氮、氧或硫的5-7个成员的环，包括环烷基、环烯基、芳基或杂芳基。
• Pentadieneamides
  申请人：Hoffmann-La Roche Inc.

  公开号：US04788206A1

  公开（公告）日：1988-11-29

  Compounds of the formula ##STR1## Y is O ir S, *A is paraphenylene or *----(CH.sub.2)n----(X).sub.m --(CH.sub.2).sub.r ----, X is O, S or --CH.dbd.CH--, n or r, independently, are integers from 0 to 3, s is an integer from 0 to 1, m is an integer from 0 to 1, provided that when m is 1, n+s must be at least 2, R.sub.1 and R.sub.2, independently, are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, Het, aryl, R.sub.3, R.sub.4 and R.sub.8, independently, are hydrogen, lower alkyl, aryl, R.sub.5 and R.sub.6, independently, are hydrogen or lower alkyl, R.sub.7 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen, oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R.sub.6 and R.sub.7 are different, their enantiomers and racemic mixtures thereof, when R.sub.1 and R.sub.2 are different, their geometric isomers, and pharmaceutically acceptable acid addition salts thereof, are described. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characerized by excess platelet activating factor or for the prevention and treatment of cardiovascular disease, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.

  式##STR1##的化合物，其中Y为O或S，*A为对苯基或*----（CH.sub.2）n----（X）.sub.m--（CH.sub.2）.sub.r----，X为O、S或--CH.dbd.CH--，n或r独立地为0至3的整数，s为0至1的整数，m为0至1的整数，但当m为1时，n+s必须至少为2，R.sub.1和R.sub.2独立地为氢、低碳基、环烷基、低烯基、Het、芳基，R.sub.3、R.sub.4和R.sub.8独立地为氢、低碳基、芳基，R.sub.5和R.sub.6独立地为氢或低碳基，R.sub.7为氢、低碳基、环烷基、Het-低碳基或芳基，Het为单环5-或6-成员杂芳基或含有从氮、氧和硫中选择的一个或两个杂原子的双环杂芳基基团，该基团可以被低碳基、卤素或芳基取代，星号表示附着点，当R.sub.6和R.sub.7不同时，它们的对映异构体和混合物，当R.sub.1和R.sub.2不同时，它们的几何异构体，以及其药学上可接受的酸加成盐。式I的化合物表现为血小板活化因子（PAF）拮抗剂的活性，因此在过量血小板活化因子或预防和治疗心血管疾病、肺部疾病、免疫性疾病、炎症性疾病、皮肤病、休克或移植排斥等疾病状态中有用。